A new benchtop bioreactor protocol has been developed to standardize the production of macrophages derived from induced pluripotent stem cells (iPSCs). The technology offers a simplified approach to generating these immune cells at intermediate scale, addressing manufacturing challenges in the field.
The protocol focuses on iPSC-derived macrophages, which are immune cells that play crucial roles in the body's defense system and tissue repair processes. The standardized approach aims to improve consistency and scalability compared to traditional cell culture methods.